Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors
Status:
Recruiting
Trial end date:
2024-04-30
Target enrollment:
Participant gender:
Summary
This phase I trial studies the sides effects and best dose of sapanisertib, carboplatin, and
paclitaxel in treating patients with malignant solid tumors that have come back (recurrent)
or do not respond to treatment (refractory). Sapanisertib may stop the growth of tumor cells
by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as
carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either
by killing cells, by stopping them from dividing, or by stopping them from spreading. Giving
sapanisertib, carboplatin, and paclitaxel may work better in treating patients with malignant
solid tumors.